PARP inhibitor

1 Drug classified under this drug class

PARP inhibitor. Rucaparib 200mg, 250mg, 300mg.
F. C. TAB.:60. The recom. dose is 600 mg (two 300 mg tabs.) taken orally twice dly. with / without food.
Cont. tmt. until dis. progress. or unaccept. toxic.
If a pt. misses a dose, instruct the pt. to take the next dose at its scheduled time. Vomited doses should not be replaced.
To manage adverse reactions, consider interruption of tmt. or dose reduct.
Recom.dose reductions: Starting Dose:  600 mg ×2/d(two 300 mg tab.).
1^st Dose Reduct.: 500 mg ×2/d (two 250 mg tab.).
2^nd  Dose Reduct.: 400 mg ×2/d (two 200 mg tab.).
3^rd  Dose Reduct.: 300 mg ×2/d (one 300 mg tab.).
Indicated for the maint. tmt. of adult pts. with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemother.
Tmt. of adult pts. with deleterious BRCA mutat. (germline and/or somatic)-assoc. epithelial ovarian, fallopian tube, or prim. peritoneal cancer who have been treated with two or more chemotherapies.
C/I: Hypersens.